SAN DIEGO, May 23, 2006 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (Swiss:ATLN.SW - News) announced today that data presented from the BUILD program (Bosentan Use in Interstitial Lung Disease) at the American Thoracic Society (ATS) conference provide a strong rationale to further evaluate the safety and efficacy of bosentan in a morbidity/mortality-driven Phase III study in patients suffering from idiopathic pulmonary fibrosis (IPF).
